Related Experiment Video
Updated: Jan 26, 2026

A BW Reporter System for Studying Receptor-Ligand Interactions
Published on: January 7, 2019
ITE, an endogenous aryl hydrocarbon receptor ligand, suppresses endometrial cancer cell proliferation and migration
Yiding Bian1, Yiran Li2, Garima Shrestha1
1Clinical and Translational Research Center, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai, PR China.
Background:
Identification of new molecular targets for the treatment of endometrial cancer (EC) is an important clinical goal, especially for the patients which were resistant to conventional therapies. The aryl hydrocarbon receptor (AhR) is a ligand- activated transcription factor known primarily as the mediator of dioxin toxicity. However, the AhR can also inhibit cellular proliferation in a ligand-dependent manner and act as a tumor suppressor in mice, thus may be a potential anticancer target. In this study, we investigated if the endogenous AhR ligand 2-(1'H-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE) regulated proliferation and migration of EC cells via AhR.
Methods:
We used quantitative real-time PCR and western blot to assess the expression of AhR in EC tissues and paired adjacent normal tissues. In addition, we conducted transwell assay to test whether the treatment of ITE altered the locomotive potential and proliferation of EC cells. Next, we conducted mouse xenograft models to further explore the in vivo effect of ITE.
Results:
We found that the AhR protein and RNA levels were increased mildly in EC tissues relative to the para-tumor normal endometrial tissues. Besides, ITE suppressed EC cells proliferation and migration in vitro, and also suppressed EC cells xenograft growth in mice.
Conclusions:
Our results strongly supported the possibility of using the ITE as a small molecular compound for the treatment of EC.
Insights
The aryl hydrocarbon receptor (AhR) ligand, ITE, suppressed endometrial cancer (EC) cell proliferation and migration. This study supports ITE as a potential therapeutic for EC treatment.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Endometrial cancer (EC) requires novel therapeutic targets, particularly for therapy-resistant cases.
- The aryl hydrocarbon receptor (AhR), a transcription factor, exhibits tumor-suppressive properties.
- Investigating endogenous AhR ligands like ITE offers a potential treatment strategy.
Purpose of the Study:
- To determine if the endogenous AhR ligand, ITE, influences EC cell proliferation and migration via AhR.
- To evaluate AhR expression in EC tissues compared to normal tissues.
Main Methods:
- Quantitative real-time PCR and Western blot analyzed AhR expression in EC and normal tissues.
- Transwell assays assessed ITE's impact on EC cell proliferation and migration in vitro.
- Mouse xenograft models evaluated ITE's in vivo efficacy.
Main Results:
- AhR expression was mildly elevated in EC tissues versus adjacent normal tissues.
- ITE treatment inhibited EC cell proliferation and migration in vitro.
- ITE suppressed tumor growth in mouse xenograft models.
Conclusions:
- ITE demonstrates significant anticancer effects against endometrial cancer cells in vitro and in vivo.
- ITE represents a promising small molecule therapeutic candidate for endometrial cancer treatment.
Related Concept Videos
Cancer Cell Migration through Invadopodia
Ligand Binding and Linkage
Internal Receptors
Ligand-Gated Ion Channel Receptor: Gating Mechanism
Cell Migration
Cell Migration

